Literature DB >> 26498648

Epidemiology of haemolytic uremic syndrome in children. Data from the North Italian HUS network.

Gianluigi Ardissino1, Stefania Salardi2, Elisa Colombo2, Sara Testa2, Nicolò Borsa-Ghiringhelli2, Fabio Paglialonga2, Valentina Paracchini2, Francesca Tel2, Ilaria Possenti2, Mirco Belingheri2, Cristina Felice Civitillo2, Stefano Sardini3, Rossella Ceruti3, Carlo Baldioli4, Paola Tommasi5, Luciana Parola6, Fiorella Russo7, Silvana Tedeschi2.   

Abstract

UNLABELLED: Despite the severity of HUS and the fact that it represents a leading cause of acute kidney injury in children, the general epidemiology of HUS is all but well documented. The present study provides updated, population-based, purely epidemiological information on HUS in childhood from a large and densely populated area of northern Italy (9.6 million inhabitants, 1.6 million children). We systematically reviewed the files concerning patients with STEC-HUS and atypical HUS (aHUS) over a 10-year observation period (January 2003-December 2012). We included all incident cases with a documented first episode of HUS before the age of 18 years. We identified 101 cases of HUS during the 10 years. The overall mean annual incidence was 6.3 cases/million children aged <18 years (range 1.9-11.9), and 15.7/million of age-related population (MARP) among subjects aged <5 years; aHUS accounted for 11.9 % of the cases (mean incidence 0.75/MARP). The overall case fatality rate was 4.0 % (3.4 % STEC-HUS, 8.3 % aHUS).
CONCLUSION: Given the public health impact of HUS, this study provides recent, population-based epidemiological data useful for healthcare planning and particularly for estimating the financial burden that healthcare providers might have to face in treating HUS, whose incidence rate seems to increase in Northern Italy. WHAT IS KNOWN: • HUS is a rare disease, but it represents the leading cause of acute kidney injury in children worldwide. • STEC-HUS (also called typical, D + HUS) is more common compared to atypical HUS, but recent, population-based epidemiological data (incidence) are scanty. What is New: • Comprehensive, population-based epidemiological data concerning both typical and atypical HUS based on a long observational period.

Entities:  

Keywords:  Acute kidney injury; Children; Epidemiology; Haemolytic uremic syndrome; Incidence

Mesh:

Year:  2015        PMID: 26498648     DOI: 10.1007/s00431-015-2642-1

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  35 in total

1.  [Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia].

Authors:  C GASSER; E GAUTIER; A STECK; R E SIEBENMANN; R OECHSLIN
Journal:  Schweiz Med Wochenschr       Date:  1955-09-20

2.  Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.

Authors:  Lothar Bernd Zimmerhackl; Johannes Hofer; Gérard Cortina; Walter Mark; Reinhard Würzner; Therese C Jungraithmayr; Gus Khursigara; Kay O Kliche; Wolfgang Radauer
Journal:  N Engl J Med       Date:  2010-05-06       Impact factor: 91.245

Review 3.  Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange.

Authors:  William F Clark
Journal:  Semin Dial       Date:  2012-02-07       Impact factor: 3.455

4.  Eculizumab for atypical hemolytic-uremic syndrome.

Authors:  Jens Nürnberger; Thomas Philipp; Oliver Witzke; Anabelle Opazo Saez; Udo Vester; Hideo Andreas Baba; Andreas Kribben; Lothar Bernd Zimmerhackl; Andreas R Janecke; Mato Nagel; Michael Kirschfink
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

Review 5.  Atypical hemolytic-uremic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

6.  Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv.

Authors:  T C Thomas; S A Rollins; R P Rother; M A Giannoni; S L Hartman; E A Elliott; S H Nye; L A Matis; S P Squinto; M J Evans
Journal:  Mol Immunol       Date:  1996-12       Impact factor: 4.407

Review 7.  Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura.

Authors:  P Ruggenenti; M Noris; G Remuzzi
Journal:  Kidney Int       Date:  2001-09       Impact factor: 10.612

8.  Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.

Authors:  J Zuber; M Le Quintrec; S Krid; C Bertoye; V Gueutin; A Lahoche; N Heyne; G Ardissino; V Chatelet; L-H Noël; M Hourmant; P Niaudet; V Frémeaux-Bacchi; E Rondeau; C Legendre; C Loirat
Journal:  Am J Transplant       Date:  2012-09-07       Impact factor: 8.086

9.  Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study.

Authors:  Angela Gerber; Helge Karch; Franz Allerberger; Hege M Verweyen; Lothar B Zimmerhackl
Journal:  J Infect Dis       Date:  2002-08-02       Impact factor: 5.226

10.  Strategies for surveillance of pediatric hemolytic uremic syndrome: Foodborne Diseases Active Surveillance Network (FoodNet), 2000-2007.

Authors:  Kanyin L Ong; Mirasol Apostal; Nicole Comstock; Sharon Hurd; Tameka Hayes Webb; Stephanie Mickelson; Joni Scheftel; Glenda Smith; Beletshachew Shiferaw; Effie Boothe; L Hannah Gould
Journal:  Clin Infect Dis       Date:  2012-06       Impact factor: 9.079

View more
  16 in total

1.  Role of climate in the spread of shiga toxin-producing Escherichia coli infection among children.

Authors:  Fiorella Acquaotta; Gianluigi Ardissino; Simona Fratianni; Michela Perrone
Journal:  Int J Biometeorol       Date:  2017-04-07       Impact factor: 3.787

2.  A simple prognostic index for Shigatoxin-related hemolytic uremic syndrome at onset: data from the ItalKid-HUS network.

Authors:  Gianluigi Ardissino; Francesca Tel; Sara Testa; Fabio Paglialonga; Selena Longhi; Laura Martelli; Silvia Consolo; Damiano Picicco; Antonella Dodaro; Laura Daprai; Rosaria Colombo; Milena Arghittu; Michela Perrone; Giovanna Chidini; Stefano Scalia Catenacci; Isabella Cropanese; Dario Consonni
Journal:  Eur J Pediatr       Date:  2018-08-10       Impact factor: 3.183

3.  Complement Gene Variants and Shiga Toxin-Producing Escherichia coli-Associated Hemolytic Uremic Syndrome: Retrospective Genetic and Clinical Study.

Authors:  Véronique Frémeaux-Bacchi; Anne-Laure Sellier-Leclerc; Paula Vieira-Martins; Sophie Limou; Theresa Kwon; Annie Lahoche; Robert Novo; Brigitte Llanas; François Nobili; Gwenaëlle Roussey; Mathilde Cailliez; Tim Ulinski; Georges Deschênes; Corinne Alberti; François-Xavier Weill; Patricia Mariani; Chantal Loirat
Journal:  Clin J Am Soc Nephrol       Date:  2019-01-23       Impact factor: 8.237

4.  Clinical features in a series of 258 Japanese pediatric patients with thrombotic microangiopathy.

Authors:  Akira Ashida; Hideki Matsumura; Toshihiro Sawai; Rika Fujimaru; Yuko Fujii; Akihiko Shirasu; Hyogo Nakakura; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2018-01-19       Impact factor: 2.801

5.  Hemoglobinuria for the early identification of STEC-HUS in high-risk children: data from the ItalKid-HUS Network.

Authors:  Valentina Capone; Maria Cristina Mancuso; Giacomo Tamburini; Giovanni Montini; Gianluigi Ardissino
Journal:  Eur J Pediatr       Date:  2021-03-23       Impact factor: 3.183

6.  Infection in Patients with Suspected Thrombotic Microangiopathy Based on Clinical Presentation.

Authors:  Benjamin Thoreau; Florent von Tokarski; Adeline Bauvois; Guillaume Bayer; Christelle Barbet; Sylvie Cloarec; Elodie Mérieau; Sébastien Lachot; Denis Garot; Louis Bernard; Emmanuel Gyan; Franck Perrotin; Claire Pouplard; François Maillot; Philippe Gatault; Bénédicte Sautenet; Emmanuel Rusch; Véronique Frémeaux-Bacchi; Cécile Vigneau; Fadi Fakhouri; Jean-Michel Halimi
Journal:  Clin J Am Soc Nephrol       Date:  2021-09       Impact factor: 10.614

Review 7.  Shiga Toxin-Associated Hemolytic Uremic Syndrome: Specificities of Adult Patients and Implications for Critical Care Management.

Authors:  Benoit Travert; Cédric Rafat; Patricia Mariani; Aurélie Cointe; Antoine Dossier; Paul Coppo; Adrien Joseph
Journal:  Toxins (Basel)       Date:  2021-04-26       Impact factor: 4.546

8.  Fecal diagnostics in combination with serology: best test to establish STEC-HUS.

Authors:  Kioa L Wijnsma; Sheila A M van Bommel; Thea van der Velden; Elena Volokhina; Michiel F Schreuder; Lambertus P van den Heuvel; Nicole C A J van de Kar
Journal:  Pediatr Nephrol       Date:  2016-05-30       Impact factor: 3.714

9.  Characterisation of STEC and other diarrheic E. coli isolated on CHROMagar™STEC at a tertiary referral hospital, Cape Town.

Authors:  John Bosco Kalule; Karen H Keddy; Mark P Nicol
Journal:  BMC Microbiol       Date:  2018-06-08       Impact factor: 3.605

10.  Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis.

Authors:  Gérard Socié; Marie-Pierre Caby-Tosi; Jing L Marantz; Alexander Cole; Camille L Bedrosian; Christoph Gasteyger; Arshad Mujeebuddin; Peter Hillmen; Johan Vande Walle; Hermann Haller
Journal:  Br J Haematol       Date:  2019-02-15       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.